At Public Good Pharma, we are advancing cost-effective healthcare through a series of Interventional Pharmacoeconomics (IVPE) clinical trials. These trials aim to validate lower-cost therapies as alternatives to expensive specialty drugs. Below are our five primary IVPE use cases, with supporting links to relevant studies:

 

 

1. Oncology Dose Optimization

    • Study: Dose de-escalation of Pembrolizumab ($120k+ annually) and Nivolumab ($150k+ annually), where payers are currently charged over $30b annually.

    • Outcome: Validating lower dosing regimens to save over 50% annually per member and reduce side-effects + identifying biomarkers and adjunct therapies for better outcomes. 

  •  

 

2. GLP-1 Dose Optimization

    • Study: Comparison of GLP-1 treatments ($12-14k+ annually) to gradual tapering to a behavioral and dietary intervention ($2k annually) for sustainable weight loss.

    • Outcome: Supporting affordable behavioral interventions for long-term obesity management with cost savings + identifying biomarkers for tapering with better outcomes. 

  •  

 

3. Orphan Drug Development

    • Study: Comparison of Ravicti ($800k annually) vs. ATX-018 ($80k annually) for Urea Cycle Disorder.

    • Outcome: Expected 20% cost savings of ~$160k annually per member enrolled during the trial and 90% cost-savings compared to current price of Ravicti upon FDA approval.

 

4. Biosimilar Repurposing

    • Study: Comparison of Ocrelizumab ($80k annually) vs. Rituximab biosimilar ($8k annually) for Multiple Sclerosis.

    • Outcome: Immediate savings of ~$16k annually per member during the trial and ~90% savings compared to current price of Ocrelizumab upon FDA approval.

 

5. Generic Drug Repurposing

    • Study: Comparison of Esketamine ($25k annually) vs. IV/IM Ketamine (<$1k annually) for Treatment-Resistant Depression.

    • Outcome: Racemic IV/IM ketamine is 100% bioavailable and likely non-inferior or superior to esketamine at less than 1/400th of the cost, offering immediate and long-term cost reductions.

 

 

Our pipeline reflects a commitment to improving healthcare affordability while maintaining the highest standards of patient outcomes. Explore these and other studies to understand how we are driving innovation in cost-containment strategies